Inmed Pharmaceuticals Inc. (INM) has released an update.
InMed Pharmaceuticals Inc. has reported a successful third quarter in fiscal 2024, with a stable cash position of $7.9 million and positive preclinical results for its Alzheimer’s and dry AMD treatments. The company’s pharmaceutical pipeline shows promising advancement, particularly with INM-901 for Alzheimer’s, which demonstrated reduced neuroinflammation and improved neuronal function in preclinical tests. Moreover, InMed’s subsidiary BayMedica maintained profitability, signaling a steady growth in the commercial side of the business.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
